Long-Term Statin Therapy Affects the Severity of Chronic Gastritis

Helicobacter

Volumn 15, Issue 6, 2010, Pages 510-515

  Nseir, William ^a   Khateeb, Julnar ^a   Tatour, Imad ^a   Haiek, Samah ^a   Samara, Mousa ^a   Assy, Nimer ^b,c  

^a Israel   (Israel)

^b Rebecca Sieff Government Hospital   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Chronic gastritis; Helicobacter pylori; Statin use

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHRONIC GASTRITIS; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTROSCOPY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; C-REACTIVE PROTEIN; CHRONIC DISEASE; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 78349267131     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00803.x     Document Type: Article

References (50)

1. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995;108:917-24.
2. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991;324:1043-8.
3. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
4. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siureala M. Gastric risk of chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173-7.
5. Huang JQ, Sridhar S, Chen RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
6. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
7. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
8. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumor necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991;32:1473-7.
9. Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol 1998;81:32B-5B.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
12. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
13. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwalde E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction on patients with average cholesterol levels. Circulation 1998;98:839-44.
14. Noach LA, Bosma NB, Jansen J, Hoek FJ, Van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425-9.
15. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocytes cell line. Int J Immunopharmacol 1996;18:669-75.
16. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD 11 b expression and CD 11b- dependent adhesion of monocytes to endothelium and reduce increased adhesiveness' of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.
17. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;162(12 Suppl):S3-23.
18. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002;23:482-6.
19. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21.
20. Blanco-Colio LM, Munoz-Garcia B, Martin-Vetura JL, Lorz C, Diaz C, Hernandez G, Egido J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003;108:1506-13.
21. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, Fujita T, Toyo-oka T, Kato T. Inhibition of Hydroxymethylglutaryl coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003;93:948-56.
22. Di Pasquale P, Cannizzaro S, Fasullo S, Ganci F, Marenghini G, Scalzo S, Giambanco F, Vitale G, Polizzi G, Paterna S. Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. Clin Sci (Lond) 2007;113:443-8.
23. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
24. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
25. Mendall MA, Goggin PM, Molineaux N, Levy J, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-9.
26. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ 1999;319:1157-62.
27. Lip GH, Wise R, Beevers G. Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H. pylori infection and hypertension. BMJ 1996;312:250-1.
28. Hara K, Morita Y, Kamihata H, Iwasaka T, Takahashi H. Evidence for infection with Helicobacter pylori in patients with acute myocardial infarction. Clin Chim Acta 2001;313:87-94.
29. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol 2006;1:63-96.
30. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-9.
31. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC, Lervang HH. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080-6.
32. Merx MW, N EA, Janssens U, Lütticken R, Schrader J, Hanrath P, Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004;109:2560-5.
33. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-7.
34. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-5.
35. Tleyjeh I, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009;169:1658-67.
36. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009;16:338.
37. Malfertheiner P, Mégraud F, O'Morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. Eur J Gastroenterol Hepatol 1997;9:1-2.
38. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
39. Figura N, Armellini D, Bugnoli M, Bayeli PF, Gennari C, Crabtree JE. Activity of omeprazole on Helicobacter pylori and relation to toxicity of strains. J Clin Pathol 1994;47:440-2.
40. Midolo PD, Turnidge JD, Lambert JR, Bell JM. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother 1996;40:1531-3.
41. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor Lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993;37:469-74.
42. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993;88:1801-2.
43. Chen JC, Huang KC, Wingerd B, Wu WT, Lin WW. HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Exp Cell Res 2004;301:05-19.
44. Heeba GH, Hassan MK, Amin RS. Gastroprotective effect of simvastatin against indomethacin-induced gastric ulcer in rats: role of nitric oxide and prostaglandins. Eur J Pharmacol 2009;607:188-93.
45. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.
46. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004;363:2015-21.
47. Goldman MD, Cohen JA. Statins to treat multiple sclerosis: friend or foe? Neurology 2008;71:1386-7.
48. Gurevich VS, Shovman O, Slutzky L, Meroni PL, Shoenfeld Y. Statins and autoimmune diseases. Autoimmun Rev 2005;4:123-9.
49. Zeiser R, Maas K, Youssef S, Dürr C, Steinman L, Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 2009;127:18-25.
50. Yamato M, Watanabe T, Higuchi K, et al. Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice. Dig Dis Sci 2007;52:2833-9.